Astria Therapeutics Inc.

ATXS | NASDAQ

Price Alert Chart Builder DCF Calculator

$12.58

$0 (0.00%)

At close: Jan 23, 2026, 4:00 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.00%

(1D)

Rating

Updated: Jan 21, 2026

25.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $718.13M

1D Range

12.58 12.58

52W Range

3.56 13.29

Valuation (TTM)

PE -5.85

PB 3.08

EV/EBITDA -3.69

Valuation (NTM)

Forward PE N/A

Forward PEG 1.01

Price Target $19.40

Cash Flow

FCF Yield -16.8%

SBC Adj. FCF Yield -18.4%

SBC Impact -9.6%

Margins

Gross Margin 100.0%

Operating Margin -19335.7%

FCF Margin -17042.9%

Growth (CAGR)

Revenue 3Y | 5Y 150.0% | 100.0%

Dil EPS 3Y | 5Y -0.2% | 81.0%

FCF 3Y | 5Y -40.6% | -34.6%

Returns

ROA -36.2%

ROE -37.7%

ROIC -42.8%

Financial Health

Net Cash

$227.72M

Current Ratio 10.78

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the Unit...

Sector Healthcare

Industry Biotechnology

Employees 78

IPO Date Jun 24, 2015

Website www.astriatx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Hold

Price Target

$20

Upside

+58.98%

Buy (0)

Hold (5)

Sell (0)

Analyst Details ➞